SenzaGen
  • Home
  • Services
    • GARD Sensitization Testing
    • Testing strategies for skin sensitization
    • Medical Device Services
    • Regulatory Toxicity Testing
    • Advisory Services
    • “Difficult-to-test” samples
    • Who we work with
  • Science
    • GARD Technology
    • Science Behind
    • Scientific Publications
    • Posters
    • Webinars
  • Company
    • About Us
    • Sustainability
    • Career
    • Partners
  • Investors
    • SenzaGen at a Glance
    • Financial Reports
    • Press Releases
    • The Share
    • Analyst Coverage
    • Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Auditor
      • Nomination Committee
      • Annual General Meeting
    • Calendar
    • Prospekt / Emission
    • Capital Markets Day 2025
  • News and Events
    • Press Releases
    • News and Insights
    • Event Calendar
  • Contact
  • Get a quote
  • Search
  • Menu Menu

EU lyfter fram SenzaGens djurförsöksfria test – världens första i sitt slag, för bedömning om kemiska ämnen kan orsaka luftvägsallergier

Kallelse till årsstämma i SenzaGen AB (publ)

Notice of Annual General Meeting of SenzaGen AB (publ)

SenzaGen utser Axel Sjöblad till ny VD – ska leda bolaget in i en expansiv försäljningsfas

SenzaGen appoints Axel Sjöblad as new CEO – mission to lead the company into an expansive sales phase

SenzaGen increases its presence in the US via a license agreement with MB Research Labs

SenzaGen utökar marknadsnärvaron i USA genom licensavtal med MB Research Labs

SenzaGen beviljas ytterligare patent i Asien

SenzaGen granted additional patent in Asia

SenzaGen takes a first step into China – cooperates with leading expert

Page 22 of 35«‹2021222324›»

Pages

  • #35927 (no title)
  • Advisory Services
  • Annual General Meeting
  • Auditor
  • ChatTest
  • Contact our experts
  • GARD for Sensitization Testing
  • Get a quote
  • Home
  • License Partners
  • Medical Device Services
  • Optionsprogram
  • Privacy Policy and Cookie Notice
  • Regulatory Toxicity Testing
  • Sales Operations Coordinator
  • Senior Business Development Manager
  • SenzaGen at a glance
  • SenzaGen at Eurotox 2024
  • SenzaGen at SOT 2025
  • Sign up for additional case studies and scientific publications
  • Sustainability
  • Thank you for your request
  • ADRA: OECD 442C
  • Advisory chemicals
  • Advisory pharma
  • Advisory Services for Cosmetics
  • Advisory Services for Medical Devices
  • Area of expertise
  • Cytotoxicity: ISO 10993-5 MTT/MEM Elution Test
  • DPRA: OECD 442C
  • EpiSensA: OECD 442D
  • Full list of regulatory tests
  • GARD Technology
  • GARDair
  • GARDskin OECD 442E, 497
  • In Vitro Biocompatibility Testing
  • Irritation: ISO 10993-23
  • Medical Device Classification
  • Medical Device Qualification
  • Non-animal testing strategies for skin sensitization
  • Overview: Biological Evaluation of Medical Devices
  • Skin corrosion: OECD TG 431
  • Skin irritation: OECD TG 439
  • Substance-based Medical Devices
  • The Expert Team
  • Board of directors
  • Capital Markets Day 2025
  • Press releases
  • Science behind
  • Services
  • Skin sensitization
  • Skin sensitization with GARD: ISO 10993-10
  • The SenzaGen Share
  • Who we work with
  • GARDair_old
  • GARDskin Dose-Response
  • Management
  • News and Insights
  • Respiratory sensitization
  • Scientific publications
  • About
  • Career
  • Difficult-to-test
  • GARDpotency: OECD TGP 4.106
  • Posters
  • Application notes
  • Event Calendar
  • Financial Reports
  • GLP
  • Investors
  • Partners
  • Corporate Governance
  • News and Events
  • Webinars
  • Calendar
  • Contact
  • Analyst Coverage
  • Presentations
  • Distributors & Contract labs
  • GARDpotency_old
  • GARDskin Dose-Response_old
  • GARDskin Medical Device_old
  • Mixed media
  • Nomination Committee
  • Partner login
  • Posts
  • Prenumerera
  • Prenumerera – fail
  • Prenumerera – success
  • Press releases-mfn
  • Prospekt och Listning NASDAQ First North
  • Regional representatives
  • Scientific advisors
  • Skin potency classification
  • Subscription
  • Test
  • Test
  • test-yearly
  • Testing
  • Testing 2
  • Ticker

Categories

  • Difficult-to-test
  • Distributors
  • Events
  • Financial events
  • Finansiella rapporter
  • GARD technology platform
  • GARDair
  • GARDpotency
  • GARDprotein
  • GARDskin
  • GARDskin Dose-Response
  • GARDskin Medical Device
  • Licence laboratories
  • News/posts
  • Photosensitization
  • Podcast
  • Posters
  • Press releases – English
  • Pressmeddelanden – Svenska
  • Regulatoriska
  • Regulatory
  • Respiratory Sensitization
  • Risk Assessment of Medical Devices
  • Scientific publications
  • Skin Sensitizing Hazard Identification
  • Skin Sensitizing Potency Assessment
  • Uncategorized

Archive

  • July 2026
  • April 2026
  • February 2026
  • December 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • June 2024
  • April 2024
  • March 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • December 2022
  • November 2022
  • October 2022
  • August 2022
  • July 2022
  • April 2022
  • March 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • September 2019
  • August 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • February 2014
  • June 2013
  • April 2013
  • December 2011
  • August 2011
  • February 2006

Quick Links

Contact
Privacy Policy (En)
Privacy Policy (Sv)
General Terms and Conditions

© SenzaGen 2026

Pages

  • Home
  • Services
  • Investors
  • Contact
  • News and Events

Follow Us

SUBSCRIBE TO PRESS RELEASES

Scroll to top

Subscribe


Prenumerera